

Table S1 Patients undergoing External Beam radiation therapy, N=162

	Year 2019, N=114	Covid-19, Year 2020, N=48	P
Pathological anatomy of the biopsy (ISUP), n (%)			
4	58 (51.3%)	27 (55.1%)	0.57
3	28 (23.9%)	13 (26.5%)	
2	22 (18.6%)	6 (12.2%)	
1	6 (5.3%)	2 (4.1%)	
Pretreatment PSA (ng/dL) (median, IQR)	11.9 (3.9–28)	10.5 (5.1–15.9)	0.646
Time between biopsy and oncology consultation (days) (median, IQR)	60.8 (8.8–112.8)	65.2 (2.1–128)	0.841
Time between oncology consultation and radiotherapy (median, IQR)	144.5 (84.05–204.8)	137.3 (75.8–192.8)	0.72
Prostate biopsy waiting time (days) (median, IQR)	33.6 (8.7–57.6)	48.8 (28.8–68.8)	0.044
Biochemical recurrence, n (%)	1 (0.8%)	1 (2.1%)	0.63

PSA, prostate specific antigen; IQR, interquartile range; ISUP, International Society of Urological Pathology.

Table S2 Patients undergoing radical prostatectomy or external beam radiation therapy stratified by year

Year 2019	LARP N=92	EBRT N=114	p
Pathological anatomy of the biopsy (ISUP), n (%)			<0.01
4	12 (12.9%)	58 (51.3%)	
3	34 (36.6%)	28 (23.9%)	
2	31 (33.3%)	22 (18.6%)	
1	14 (15.1%)	6 (5.3%)	
Pretreatment PSA (ng/dl) (median, IQR)	6.7 (2.5–10.97)	11.9 (6.9–16.9)	0.003
Pandemic Year 2020	LARP N=40	EBRT N=48	
Pathological anatomy of the biopsy, (ISUP), n (%)			< 0.01
4	5 (12.5%)	27 (56.3%)	
3	11 (27.5%)	13 (27.1%)	
2	15 (37.5%)	6 (12.5%)	
1	9 (22.5%)	2 (4.2%)	
Pretreatment PSA, (median, IQR)	6.9 (4.5–9.3)	10.5 (5.1–15.5)	0.041

PSA, prostate specific antigen; ISUP, International Society of Urological Pathology; LARP, laparoscopic assisted radical prostatectomy; EBRT, external beam radiation therapy.